Abstract 301P
Background
Cervical cancer is the most prevalent reproductive malignancy in women worldwide and estimated over 600,000 new cases and 340,000 deaths each year. Concurrent chemoradiotherapy is the standard treatment for locally advanced cervical cancer. Despite the great improvement this strategy has achieved, nearly 30% of patients will suffer distant metastases and 70% of patients may experience local recurrence. The dominance of Lactobacillus in the vaginal microenvironment of healthy women helps to establish a physiological barrier on the vaginal surface, Microbial biomarkers are effective for predicting the nonresponse for immune checkpoint inhibitor administration. It is intriguing to explore the alteration of vaginal microbial community challenged by chemoradiotherapy, also whether microorganism(s) could be used as biomarkers to predict the responsiveness of chemoradiotherapy.
Methods
A total of 126 patients with IB-IVB cervical cancer who received chemoradiotherapy in our hospital were enrolled in this study. The sampling of vaginal microbiome was carried out as we previously described, both pre- and post-treatment of each patient. Bacterial genomic DNA was extracted and 16S rRNA was sequenced from their vaginal secretions, and the results were analyzed bioinformatically.
Results
We found that the structure and composition of the vaginal microbiome changed significantly before and after radiotherapy, and radiotherapy treatment significantly changed the structure of the microorganisms, destroyed their physiological functions and disrupted the homeostasis of the microbial community. At the same time, we found that the beneficial microbial community in the vaginal microbiome decreased significantly in the relapsing group compared with the non-relapsing group before and after radiotherapy, and the microbial function and community homeostasis were significantly reduced, suggesting an unhealthy vaginal microbiome in the relapsing group.
Conclusions
We have shown that C-reactive protein and disease stage and other factors and biomarkers (such as L. iners) are important factors in predicting the recurrence of cervical cancer patients after radiotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhejiang Cancer Hospital.
Funding
Zhejiang medicine and health science and technology project.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer
Presenter: Wen-Chen Tang
Session: Poster Display
Resources:
Abstract
582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
Presenter: Haiyang Chen
Session: Poster Display
Resources:
Abstract
583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Presenter: jun Deng
Session: Poster Display
Resources:
Abstract
584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis
Presenter: Tangfeng Lv
Session: Poster Display
Resources:
Abstract
585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Presenter: Tony S.K. Mok
Session: Poster Display
Resources:
Abstract
586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
Presenter: Ning Yi Yap
Session: Poster Display
Resources:
Abstract
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Presenter: Kaihua Lu
Session: Poster Display
Resources:
Abstract
590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Presenter: Ben Markman
Session: Poster Display
Resources:
Abstract
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract